Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Amphastar Pharmaceuticals ( (AMPH) ) is now available.
On January 12, 2026, Amphastar Pharmaceuticals announced an exclusive license agreement with Nanjing Hanxin Pharmaceutical Technology for AMP-110, a fully synthetic and highly purified human adrenocorticotropic hormone (ACTH) analog intended for inflammatory and autoimmune conditions, granting Amphastar rights in the United States and Canada and giving Hanxin a non-exclusive license for other territories. Amphastar paid a $2 million upfront fee and agreed to up to $14 million in development milestones, up to $75 million in sales milestones, and annual royalties to Hanxin capped at $7.5 million and $60 million in total, while Hanxin will pay Amphastar royalties on net sales based on patents licensed from Amphastar; with AMP-110 in early-phase human clinical development and the U.S. ACTH market exceeding $684 million in 2024, the deal strengthens Amphastar’s proprietary peptide portfolio and positions it to compete in a growing therapeutic niche for conditions such as multiple sclerosis exacerbations, rheumatoid arthritis, lupus, ophthalmic inflammation, and infantile spasms.
The most recent analyst rating on (AMPH) stock is a Hold with a $30.00 price target. To see the full list of analyst forecasts on Amphastar Pharmaceuticals stock, see the AMPH Stock Forecast page.
Spark’s Take on AMPH Stock
According to Spark, TipRanks’ AI Analyst, AMPH is a Outperform.
Amphastar Pharmaceuticals scores well due to its strong financial performance and strategic growth initiatives. The company’s robust revenue growth, effective cash flow management, and low leverage are significant strengths. Technical indicators are mixed, and valuation suggests the stock is undervalued. The earnings call and recent corporate events further support a positive outlook, despite some competitive pressures and litigation impacts.
To see Spark’s full report on AMPH stock, click here.
More about Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal drug products, as well as insulin active pharmaceutical ingredients. Its products are primarily used in hospital and urgent care settings and are largely distributed through group purchasing organizations and drug wholesalers in the United States.
Average Trading Volume: 400,449
Technical Sentiment Signal: Hold
Current Market Cap: $1.27B
Find detailed analytics on AMPH stock on TipRanks’ Stock Analysis page.